Latest Insider Transactions at Bicycle Therapeutics PLC (BCYC)
This section provides a real-time view of insider transactions for Bicycle Therapeutics PLC (BCYC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BICYCLE THERAPEUTICS plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BICYCLE THERAPEUTICS plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 28
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,495
+7.51%
|
$314,930
$14.0 P/Share
|
|
Apr 27
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,636
-1.27%
|
$205,716
$31.04 P/Share
|
|
Apr 27
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,636
+2.48%
|
$92,904
$14.0 P/Share
|
|
Apr 26
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
18,611
-3.45%
|
$576,941
$31.07 P/Share
|
|
Apr 26
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,545
+5.05%
|
$203,630
$14.0 P/Share
|
|
Apr 08
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
24,838
-82.8%
|
$769,978
$31.84 P/Share
|
|
Apr 08
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
24,838
+50.0%
|
$198,704
$8.74 P/Share
|
|
Apr 05
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
162
-100.0%
|
$5,022
$31.07 P/Share
|
|
Apr 05
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
162
+50.0%
|
$1,296
$8.83 P/Share
|
|
Mar 31
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$300,000
$30.0 P/Share
|
|
Mar 31
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$80,000
$8.78 P/Share
|
|
Mar 31
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-26.1%
|
$300,000
$30.0 P/Share
|
|
Mar 17
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
7,784
-100.0%
|
$225,736
$29.0 P/Share
|
|
Mar 17
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
7,784
+50.0%
|
$62,272
$8.85 P/Share
|
|
Mar 15
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
217
-0.56%
|
$6,076
$28.0 P/Share
|
|
Mar 12
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
9,783
-10.19%
|
$273,924
$28.74 P/Share
|
|
Mar 12
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
2,216
-100.0%
|
$64,264
$29.0 P/Share
|
|
Mar 12
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
2,216
+50.0%
|
$17,728
$8.86 P/Share
|
|
Feb 05
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$3,100
$31.0 P/Share
|
|
Jan 20
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,185
-0.15%
|
$37,920
$32.12 P/Share
|
|
Jan 19
2021
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
15,000
-100.0%
|
$450,000
$30.0 P/Share
|
|
Jan 19
2021
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.59 P/Share
|
|
Jan 19
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-0.63%
|
$150,000
$30.15 P/Share
|
|
Jan 15
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-1.85%
|
$135,000
$27.01 P/Share
|
|
Jan 14
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-1.82%
|
$125,000
$25.0 P/Share
|
|
Jan 14
2021
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$250,000
$25.0 P/Share
|
|
Jan 14
2021
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$10,000
$1.6 P/Share
|
|
Dec 01
2020
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$165,000
$22.5 P/Share
|
|
Dec 01
2020
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$7,500
$1.56 P/Share
|
|
Nov 27
2020
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
530
-100.0%
|
$10,600
$20.0 P/Share
|
|
Nov 27
2020
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
530
+50.0%
|
$530
$1.56 P/Share
|
|
Nov 25
2020
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
9,781
-100.0%
|
$195,620
$20.07 P/Share
|
|
Nov 25
2020
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,781
+50.0%
|
$9,781
$1.56 P/Share
|
|
Nov 23
2020
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
17,189
-99.38%
|
$343,780
$20.1 P/Share
|
|
Nov 23
2020
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,189
+50.0%
|
$17,189
$1.56 P/Share
|
|
Jul 15
2020
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,147
-0.08%
|
$59,793
$19.33 P/Share
|
|
Jul 14
2020
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,597
-0.08%
|
$30,343
$19.27 P/Share
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
364,286
+15.69%
|
$5,100,004
$14.0 P/Share
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
139,264
+8.04%
|
-
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,454,411
+50.0%
|
-
|
|
May 28
2019
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
385,714
+16.76%
|
$5,399,996
$14.0 P/Share
|
|
May 28
2019
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,529,561
+39.69%
|
-
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
168,630
+8.7%
|
$2,360,820
$14.0 P/Share
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,529,561
+39.22%
|
-
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
71,450
+6.9%
|
-
|